News
Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...
Q1 2025 Management View CEO Sanj Patel highlighted that Kiniksa achieved $137.8 million in net product revenue for ARCALYST during Q1 2025, marking a 75% increase year-over-year. This success was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback